業(yè)務(wù)咨詢
中國(guó):
Email: marketing@medicilon.com.cn
業(yè)務(wù)咨詢專線:400-780-8018
(僅限服務(wù)咨詢,其他事宜請(qǐng)撥打川沙總部電話)
川沙總部電話: +86 (21) 5859-1500
海外:
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
Stroke is one of the most devastating diseases affecting the health and life of human beings.
TBN, a novel tetramethylpyrazine derivative armed with a powerful free radical-scavenging nitrone moiety, has been reported to reduce cerebral infarction in rats through multi-functional mechanisms of action. TBN may serve as a promising new clinical candidate for the treatment of ischemic stroke.
Six Cynomolgus macaque monkeys were used for pharmacokinetic study. TBN were given intravenously at doses of 30 and 90?mg/kg, 3 monkeys for each dose.
TBN (purity 99.3%) used in this study was synthesized by Medicilon.
Reference: